NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
How did NLSP's recent EPS compare to expectations?
The most recent EPS for NLS Pharmaceutics AG is $, expectations of $.
How did NLS Pharmaceutics AG NLSP's revenue perform in the last quarter?
NLS Pharmaceutics AG revenue for the last quarter is $
What is the revenue estimate for NLS Pharmaceutics AG?
According to of Wall street analyst, the revenue estimate of NLS Pharmaceutics AG range from $ to $
What's the earning quality score for NLS Pharmaceutics AG?
NLS Pharmaceutics AG has a earning quality score of A-/64.2669. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does NLS Pharmaceutics AG report earnings?
NLS Pharmaceutics AG next earnings report is expected in
What are NLS Pharmaceutics AG's expected earnings?
NLS Pharmaceutics AG expected earnings is $, according to wall-street analysts.
Did NLS Pharmaceutics AG beat earnings expectations?
NLS Pharmaceutics AG recent earnings of $ expectations.